scispace - formally typeset
B

Brian A. Ference

Researcher at University of Cambridge

Publications -  88
Citations -  18493

Brian A. Ference is an academic researcher from University of Cambridge. The author has contributed to research in topics: Medicine & Mendelian randomization. The author has an hindex of 30, co-authored 73 publications receiving 9598 citations. Previous affiliations of Brian A. Ference include Wayne State University & University of Oxford.

Papers
More filters
Journal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more
Journal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
Journal ArticleDOI

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

TL;DR: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
Journal ArticleDOI

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L.J. Visseren, +105 more
Journal ArticleDOI

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

TL;DR: The achieved absolute LDL-C level was significantly associated with the absolute rate of major coronary events, including coronary death or MI, for primary prevention trials and secondary prevention trials (1.5%-2.5% lower event rate); and for established nonstatin interventions that work primarily via upregulation of LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe).